Search
Crohn's Disease Paid Clinical Trials in District Of Columbia
A listing of 1 Crohn's Disease clinical trials in District Of Columbia actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 1 of 1
The state of District Of Columbia currently has 1 active clinical trials seeking participants for Crohn's Disease research studies. These trials are conducted in various cities, including Washington, Washington, D.C., Washington DC and Washington, Dc.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Pediatric IBD Study
Recruiting
Is your 2-17 year old living with Crohn's Disease or Ulcerative Colitis? A clinical trial is currently open to enroll
2-17-year-olds. Eligible participants will receive study-related medical care at no cost. Health insurance is not required.
2-17-year-olds. Eligible participants will receive study-related medical care at no cost. Health insurance is not required.
Conditions:
Ulcerative Colitis
Colitis
Ulcerative
Ulcerative Colitis (UC)
Active Ulcerative Colitis
Featured Trial
Crohn's Disease Clinical Study
Recruiting
Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.
Conditions:
Crohn's Disease
Crohn Disease
Crohns Disease
Crohn's Disease (CD)
Crohn Colitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Recruiting
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week... Read More
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
05/23/2025
Locations: Emerson Clinical Research Institute ( Site 5051), Washington, District of Columbia
Conditions: Crohn's Disease
1 - 1 of 1